WO2000046601A1 - Detecting telomerase activity - Google Patents
Detecting telomerase activity Download PDFInfo
- Publication number
- WO2000046601A1 WO2000046601A1 PCT/IB2000/000100 IB0000100W WO0046601A1 WO 2000046601 A1 WO2000046601 A1 WO 2000046601A1 IB 0000100 W IB0000100 W IB 0000100W WO 0046601 A1 WO0046601 A1 WO 0046601A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- telomerase
- cells
- solid phase
- telomerase activity
- sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
Definitions
- the present invention relates to a method for detecting telomerase activity in a sample, and to the use of a solid phase for detecting telomerase activity in a sample.
- the invention also relates to a kit for detecting telomerase activity in a sample.
- Telomeres are the specialised ends of all eukaryotic chromosomes that serves as protective caps preventing the chromosomes from fusing together and causing DNA rearrangements that can lead to karyotypic changes and genomic instability (M ⁇ ller, 1938; McClintock, 1941).
- the term "telomere” was coined by M ⁇ ller from the Greek words for "end” (telos) and "part” (meros).
- the regulatory role for telomeres in cell proliferation was postulated when it was realised that the ends of linear DNA molecules could not be replicated by any known DNA polymerases (Watson, 1972; Olovnikov, 1973).
- telomeres are in a dynamic state of equilibrium between shortening and stabilisation of lengthening (Greider and Blackburn, 1987; Morin, 1989).
- Figure 1 presents a model describing the inverse relationship between telomere length and replicative age. As telomeres shorten they will reach a critical length, which signals cell cycle arrest and initiates a senescence program. This point (Ml) represents the limit of replicative lifespan, initially described by Hayflick (1965) for human cultured fibroblasts. This property has later been documented for a variety of other cell types growing in vitro or in vivo (reviewed by Harley, 1995).
- telomeres continue to shorten until a second point is reached (M2), termed crisis, where massive cell death occurs, perhaps because of chromosome inviability due to impaired telomere function.
- M2 a second point is reached
- telomere maintenance machinery including telomerase
- the cells that emerge from M2 can divide indefinitely. Harley (1991) equated this loss of telomeric DNA with a clock that monitors the number of times a cell has divided and ultimately limits the process of division.
- telomeres are complexes of G rich simple repeated DNA and of proteins that specifically bind to it.
- Table A shows some eukaryotic organisms in which telomerase activity has been identified and the RNA component of telomerase identified and cloned (reviewed by Greider, 1996).
- the telomere sequence of each organism is shown in 5'- 3' direction, as is the sequence of the template region of the telomerase RNA. Size (nt) indicates the length of the RNAs in nucleotides.
- Human telomeres can contain up to 20 kb of tandem repeats of the hexamer TTAGGG (Moyzis et ah, 1988).
- telomere shortening has been shown to be in the range of 50 to 100 base pairs per cell generation (Harley et ah, 1990; Counter et ah, 1992; Vaziri et al., 1994).
- telomeres are a ribonucleoprotein (Greider and Blackburn, 1987; Morin, 1989) whose RNA and protein components are both essential for the synthesis of telomeric DNA.
- Telomerase RNA contains an 8- to 30-base segment that serves as template (Table A) for elongation of the 3' overhang that remains after removal of the terminal RNA primer. Telomerase generates tandem repeats of the short sequence encoded by telomerase RNA as shown in Figure 2 (associated protein components are not shown).
- the 3' end of the chromosome aligns near the 3' end of the template region of the RNA. The entire template region is complementary to -1.5 repeats of the human telomerase sequence (Table A).
- telomere extension proceeds to the 5' end of the template region.
- telomerase can translocate to begin another round of telomere synthesis (adapted from Harley and Nillenponteau, 1995). After telomerase elongation of the 3' strand, a conventional D ⁇ A polymerase probably synthesises the complementary strand.
- telomere activity was first characterised biochemically for Tetrahymena, a ciliated protozoa, by Greider and Blackburn in 1985. As the structures of all characterised telomeres are very similar, Greider and Blackburn (1985) proposed that there has to be a common mode of telomere replication in all eukaryotes. Four years later, this proposal was supported when a very similar biochemical activity was identified in the immortal human HeLa cell line (Morin, 1989). Cloning of the R ⁇ A component of Tetrahymena telomerase (Greider and Blackburn, 1989) clarified several aspects of the mechanism of action of this novel D ⁇ A polymerase.
- the predicted template region of the Tetrahymena R ⁇ A component is complementary to 1.5 repeats of the telomere sequence (Table A), a result that was confirmed by the demonstration that mutations in this region led to the predicted alterations in telomere sequence when the mutated RNA was overexpressed in vivo (Yu et al., 1990).
- Tetrahymena enzyme preferentially binds to and elongates telomeric sequence primers over nontelomeric sequences.
- telomere-like sequences other than the cognate telomere repeats will serve as efficient primers (Greider and Blackburn, 1987).
- telomerase extracted from Tetrahymena will elongate primers consisting of the telomere repeat from organisms as different as ciliates, humans, plants and yeast. This property of telomerase parallels the ability of telomeres from different organisms to function in yeast (Szostak and Blackburn, 1982; Pluta et al., 1984).
- telomerase has a general affinity for G-rich oligonucleotide sequences (Lee and Blackburn, 1993; Morin, 1991; Harrington and Greider, 1991; Collins and Greider, 1993), which differ from the high-affinity sequence-specific recognition of many DNA and RNA binding proteins.
- Telomerase activity has been detected at low level in normal peripheral blood cells and in normal bone marrow (Counter et al, 1995; Broccoli et al., 1995; Hiyama, K. et al., 1995; Weng et al., 1996; Hohaus et al, 1997). Subsequent studies have more clearly defined the cellular source. Telomerase is not detected in mature neutrophiles but B- and T-lymphocytes have activity. Unfractionated mononuclear cells from normal bone marrow also express telomerase activity, usually at the same level as peripheral blood mononuclear cells.
- telomere activity Testes and ovaries have also been shown to express telomerase activity (Kim et al., 1994; Wright et al., 1996). It is therefore reason to believe that stem cells generally will show some telomerase activity like demonstrated for the basal cells and stem cells of the skin (Taylor et al., 1996; Harle-Bachor et al., 1996; Yasumoto et al, 1996; Ramierez et al., 1997), intestinal crypt cells (Hiyama, E.
- telomere activity is repressed when inducing differentiation of immortal cells (Holt et al., 1996b; Sharma et al, 1995; Bestilny et al, 1996; Xu et al, 1996; Asai et al, 1998). This leads to the working hypothesis that there are at least two pathways for the repression of telomerase activity (Holt et al, 1996a).
- telomere activity is found in testis and ovary, while it is absent in sperm and oocytes, present in early embryogenesis, but decreases during development of the fetus and is absent in most tissues in the new-born baby (Wright et al., 1996).
- telomere length and telomerase activity were also found to be closely regulated in the course of B cell differentiation (Weng et al, 1997b). In contrast to previously characterised models of telomere shortening during somatic cell division, telomeres are significantly longer in germinal centre B cells than in either precursor naive or descendant memory B cells. Telomerase activity was markedly increased in germinal centre B cells relative to other B cell populations, correlating with increased telomere length (Weng et al, 1997b). High levels of telomerase activity are induced in naive and memory B cells by in vitro activation. These results suggest that telomerase may play a critical role in immune responses by elongating telomeres and thus preserving the replicative lifespan of germinal centre and progeny memory B cells. Expression of the RNA component of telomerase
- telomere RNA component hTR
- hTR human telomerase RNA component
- telomere expression of hTR may be necessary but not sufficient for telomerase activity, and the absence of telomerase activity in resting lymphocytes with detectable levels of hTR may reflect the failure to express sufficient levels of one or more of the other telomerase components or the presence of a dominant mechanism to repress telomerase in these cells (Weng et ⁇ ., 1997a).
- telomere maintenance in immortalisation The catalytic subunit of telomerase, hTERT (human telomerase reverse transcriptase, initially abbreviated hTRT, hEST2, hTCSl or TP2), was recently identified and cloned (Nakamura et al., 1997; Meyerson et al., 1997; Kilian et al, 1997).
- hTERT human telomerase reverse transcriptase, initially abbreviated hTRT, hEST2, hTCSl or TP2
- telomere catalytic subunit may be important for the regulation of telomerase activity and may give rise to proteins with different biochemical functions (Kilian et al, 1997; Ulaner et al, 1998).
- telomere expression positively correlates with the known telomerase status of tissues and cell lines and occurs preferentially in cell lines in vitro after the cells have undergone crisis, in normal tissues with a significant stem cell component and in a range of tumours (Nakamura et al, 1997; Meyerson et al, 1997; Kilian et al, 1997; Kolquist et al, 1998; Kanaya et al, 1998).
- These findings define an important component of the human telomerase complex and implicate its expression as the major determinant of the distribution of telomerase activity in mammalian cells.
- telomere specific and reverse transcriptase (RT) motifs reduce or abolish telomerase activity (Weinxich et al, 1997).
- RT reverse transcriptase
- telomere maintenance or elongation It was recently shown that hTERT mRNA is present in specific subsets of some normal, telomerase negative tissues thought to have long term proliferative capacity, but the level may not signify a level of telomerase that is above the threshold required for telomere maintenance or elongation (Kolquist et al, 1998).
- telomere- and telomerase associated proteins are required for full telomerase assembly, function and regulation.
- Two protein subunits have been identified in Tetrahymena (p80 and p95) that appear to be associated with the telomerase complex but not being the catalytic subunit (Collins et al, 1995). This led to the identification of mammalian homologues, TP1 (Harrington et al, 1997; Nakayama et al, 1997), which RNA transcript does not correlate with the telomerase activity.
- telomeres form a specialised nucleoprotein complex (Chong et al., 1995). Recently it was reported that this protein, TRF1, is involved in regulating the telomere length (van Steensel and de Lange, 1997).
- telomere activity in immortal human cell populations and malignant tumours and its general absence prior to this stage has led to the suggestions that cellular immortalisation and telomerase reactivation are essential for the progression and clinical lethality of most human tumours, but not for their formation (Kim et al, 1994; Edington et al, 1995).
- tumour suppressors such as p53 and pRb, which allows cells to overcome Ml and have an extended lifespan (Figure 1.)
- Figure 1. directly leads to the genomic instability that contributes to the accumulation of additional mutations (Harley, 1991, 1995).
- Maintenance of telomeres at very short lengths, as is the case for many human tumours may be sufficient to stabilise chromosome ends enough for cell division. Yet, this stabilisation may not totally eliminate the potential for increased chromosomal recombination, which could contribute to genomic instability and tumour progression.
- telomere activity is called TRAP assay (telomeric repeat amplification protocol) (Kim et al., 1994).
- the cells are lysed in a way that keeps the telomerase activity intact.
- the specific telomeric product is amplified by PCR for detection.
- This method has simplified the work in the telomerase field a lot. To date nearly all types of human neoplasia have been screened for the presence of the enzyme, and 759 of 895 (i.e. 85%) of malignant tumours tested have been shown to express telomerase activity (Shay and Bacchetti, 1997).
- telomere negative somatic cells should indicate that the presence of the RNA component is not the only factor required for enzymatic activity. This is in accordance with the findings that the levels of hTR is not affected when telomerase activity is decreased during experimentally induced differentiation of tumour cells in vitro (Feng et al, 1995), and that the level of hTR in a variety of different tumours is not shown to predict the level of telomerase activity in the tumour (Avilion et al, 1996).
- hTERT correlates with telomerase activity (Nakamura et al., 1997; Meyerson et al, 1997; Kilian et al, 1997; Kolquist et al, 1998; Kanaya et al, 1998).
- Expression of hTERT is up-regulated concomitant with the activation of telomerase during immortalisation of cultured cells and down-regulated during in vitro cellular differentiation (Meyerson et al., 1997).
- telomere length may be a diagnostic and prognostic marker and itself a target for therapy.
- telomerase may be the most specific and universal cancer marker known to date.
- a number of studies have shown that telomerase expression correlates with clinical outcome in some cancers (reviewed in Bacchetti and Counter, 1995; Shay and Wright, 1996; Shay and Bacchetti, 1997; Le et al, 1998; Yoshida et al, 1998), which means that telomerase can be used as a prognostic marker as well as a diagnostic marker in these kinds of cancer.
- telomere activity increases with cancer disease severity (Counter et al, 1995; Hiyama E. et al, 1995a, 1996a), but there is a substantial variability even among tumours of the same type and stage.
- the data collected indicate that telomerase is a prevalent and specific tumour marker (Bacchetti and Counter, 1995; Leber and Bacchetti, 1996; Shay and Wright, 1996; Shay and Bacchetti, 1997).
- the presence of telomerase activity can indicate presence of either normal telomerase-competent cells or cancer cells.
- the absence of telomerase-activity can indicate either presence of telomerase-silent normal cells or the quiescent state of telomerase-competent cells.
- telomere activity is limited unless careful control experiments are done. This can be illustrated by the fact that certain haemotopoietic cells show low levels of telomerase activity, which complicates the detection of circulating cancer cells in blood and bone marrow.
- telomerase activity was found in 85% of gastric tumours and the majority of the negative cases was early-stage (Hiyama E. et al, 1995b; Tahara et al, 1996). Chadeneau et al (1995) showed that telomerase activity could not be detected in adenomatous polyps of the colon whereas it could be detected in colorectal carcinomas. Thus for carcinomas and neuroblastomas there may be a prognostic value in knowing the telomerase status. Telomerase expression can be a useful marker for predicting outcome of disease. In addition, such a novel marker might provide new information for determining appropriate treatment for a cancer patient.
- telomerase activity was inhibited by cisplatin treatment in human testicular cancer (Burger et al, 1997), and that the telomerase activity in different malignant cells was inhibited when introducing retroviruses expressing RNA complementary to the template region of hTR (Bisoffi et al, 1998).
- the value of a prognostic marker will be most evident where there are clearly defined treatment options that are dependent upon the aggressiveness of the tumour in question.
- a telomerase-based prognostic assay could for example differentiate node-negative breast cancer patients either by screening of the primary tumour for telomerase expression level or screening of circulating cancer cells (micrometastasis).
- Telomerase detection may be a prognostic marker during treatment of cancer since there is evidence for that telomerase activity can be turned off by inducing cancer cells to differentiate (Sharma et al, 1995; Bestilny et a/., 1996; Xu et al, 1996).
- the detection system needed for this can be based on: locating cells at a site they should not be present a component present in cancer cells but not in normal cells a combination of the two above
- the technology presently used is based on microscopic detection of cancer cells. This can be made easier by selective staining of cancer cells made possible by cells present at an abnormal location. An example of this is staining of cytokeratin, an epithelial cell-specific protein also found in carcinoma cells circulating in blood or bone marrow. Another possibility is to isolate mRNA and do an amplification of genes expressed more or less specifically in cancer cells. The latter approach is very difficult since even tissue-specific genes is normally present at a very low level in so called "non-expressing cells". There can be a big difference in expression, for example 10 000 copies per cancer cell and 1 mRNA per normal cell. However, this is more than outweighed by the ratio of rare cancer cells to normal cells, for example 1 per million (e.g.
- the present invention aims to overcome the disadvantages of the prior art.
- the present invention provides a method for detecting telomerase activity in a sample, which comprises:
- the present invention provides use of a solid phase for separating telomerase from a sample by treating the sample with the solid phase so as to bind the telomerase thereto .
- the present invention provides use of a solid phase for detecting telomerase activity in a sample by treating the sample with the solid phase so as to bind the telomerase thereto and assaying the solid phase for telomerase activity.
- the present invention provides a kit for detecting telomerase activity, comprising a solid phase for binding telomerase and one or more components for assaying for telomerase activity.
- the present invention provides use of a kit as described herein, for the detection of cancer cells.
- the present invention provides a component of an assay system for detecting telomerase activity, which comprises a solid phase for binding telomerase on which is present a substrate for telomerase elongation.
- FIGURE 1 shows a graph of telomere length against replicative age for various cell types.
- FIGURE 2 shows a representation of the predicted mechanism of human telomerase.
- FIGURE 3 shows a polyacrylamide gel as described in Example 1 illustrating the detection limit for the telomerase repeat assay.
- FIGURE 4 shows a polyacrylamide gel as described in Example 2 illustrating the isolation of telomerase activity with magnetic beads.
- FIGURE 5 shows a polyacrylamide gel as described in Example 3 illustrating the isolation of telomerase activity using Dynabeads DNA DIRECT.
- FIGURE 6 shows a polyacrylamide gel as described in Example 4 illustrating the isolation of telomerase with increasing quantities of epoxide beads.
- FIGURE 7 shows a polyacrylamide gel as described in Example 5 illustrating a test for the presence of genomic DNA in the remaining lysate fractions after bead-based telomerase isolation.
- FIGURE 8 shows a SDS-PAGE gel as described in Example 6 illustrating the binding of proteins to polymer magnetic beads.
- FIGURE 9 shows a polyacrylamide gel as described in Example 7 illustrating the sensitivity and reliability of the telomerase isolation method.
- FIGURE 10 shows a polyacrylamide gel as described in Example 8 illustrating the enricliment of circulating carcinoma cells in blood with subsequent detection of telomerase activity.
- FIGURE 11 shows a polyacrylamide gel as described in Example 9 illustrating telomerase activity in micrometastatic cells in pleura from a breast cancer patient.
- FIGURE 12 shows a flowchart illustrating the combination of the telomerase isolation with the TRAP assay and mRNA isolation from the lysate for detection of micrometastatic cells.
- FIGURE 13 shows a flowchart illustrating a method for detecting telomerase activity in colonic cells isolated from faeces.
- telomerase activity is called TRAP assay (telomeric repeat assay protocol) (Kim et al. 1994).
- TRAP assay telomeric repeat assay protocol
- the cells of interest are lysed in a way that keeps the telomerase activity intact.
- a synthetic oligonucleotide is added to the lysate, and the mixture
- telomere 13a is incubated at 37° C to allow for the telomerase to use this oligo for elongation.
- This specific telomeric product is amplified by PCR for detection.
- this method still involves the analysis of 32 P -labelled reaction products by polyacrylamide gel electrophoresis (Kim et al. 1994, Piatyszek et al. 1995). Modifications such as introduction of an internal standard (Wright et al. 1995) have improved the reliability of the assay. A further improvement is done by combining the TRAP assay with a scintillation proximity assay technology (SPA) (Savoysky et al. 1996). This increases the speed of the assay by omitting the electrophoresis step.
- SPA scintillation proximity assay technology
- the detection limit is about 100 cells per assay
- the telomerase activity could clearly be detected with as few as 10 cells.
- Improved primer design and development of a semi-quantitative assay has also increased the reliability of the assay (Kim and Wu 1997).
- telomerase assay could be in the diagnosis of cancer through obtainable body fluids such as blood, bone marrow, urine, sputum and materials derived from various washes. Fine needle biopsies, cervical smears and analysis of cells in the faeces might also be useful for improved early diagnosis of primary cancer.
- the TRAP assay has been shown to be prone to inhibition by some lysates - this is especially true if too much material is analysed (Broccoli et al. 1995, Norrback 1996). For each extract initial TRAP reactions must be performed to identify conditions under which the TRAP reaction are not inhibited. This has usually been done by measuring the protein content in the lysate and using samples containing
- telomere-positive cells represent a minor fraction of the sample for example stem cells in blood, bone marrow or tissues or cancer cells metastasis in lymph nodes or circulating micrometastasis.
- telomere complexes We have been using different kinds of magnetic Dynabeads, Antibody coated beads of 2,8 (Example 2, 8 and 9) or 4,5 ⁇ m size, uncoated magnetic beads of the same sizes and Dynabeads DNA DIRECT (Example 3 and 4), and all bead types tested so far isolate the telomerase complexes.
- telomerase works on chromosomal DNA ends made it natural to put forward a hypothesis that telomerase was bound indirectly to the magnetic beads via chromosomal DNA. This hypothesis was supported when it was shown that beads developed for isolation of DNA also could be used for capture of telomerase (Example 3). To verify this assumption, it had to be proven that DNA was present in the bead fraction after isolation of telomerase, but the hypothesis had to be rejected since DNA remained in the lysate after telomerase isolation (Example 4).
- the magnetic particles used in this study except from those developed for DNA isolation, were coated with aromatic epoxide monomers and had a hydrophilic surface, which in general will immobilise biomolecules.
- This hydrophilic surface has an advantage over hydrophobic surfaces, as denaturation of the captured enzyme will be avoided and thereby reduce loss of enzymatic activity over time.
- the lysis buffer in the TRAPeze kit includes 0,5 % CHAPS, 1 mM EGTA, 5 mM ⁇ -mercaptoethanol and 0.1 mM
- telomerase complexes attached to the magnetic beads remain enzymatically active after removal of the cell lysate. This implies that the beads with the captured and purified telomerase complexes can be added directly to the TRAP mix for enzymatic elongation of the telomere with subsequent PCR amplification of the telomeric product.
- the isolated telomerase can also be used for any other kind of method for testing telomerase activity.
- telomerase activity follows the magnetic beads simplifies greatly the telomerase assay.
- the main advantage of the method invented is the separation of the telomerase complex from the lysate, which may contain inhibitors of the assay causing false negatives. Too much cell extract added to the TRAP assay can also inhibit the telomerase activity (Broccoli et al, 1995). Negative TRAP assays need careful interpretation as demonstrated when phenol-chloroform extraction, after the telomerase extension reaction, of previously telomerase negative samples revealed presence of PCR inhibitors in 30% of these samples (Sugino et al, 1997).
- the complex of beads and telomerase was separated from the cell lysate using a magnet. In this way interfering agents were removed along with the lysate, before the complex of telomerase and beads was resuspended in fresh lysis buffer or dH 2 O for telomere synthesis and PCR amplification.
- a clean bead fraction also leads to an improved reliability of the assay even when working close to the detection limit (Example 7). Removal of most of the contaminating factors reduces the probability of obtaining false negative results, and hence increases the reliability of the TRAP method. This will presumably also be an advantage where there are problems with false negative tests due to the mucous nature of some tumours
- Magnetic beads could be used to isolate telomerase and remove the viscous lysate prior to the enzymatic synthesis.
- the beads can still be used to achieve capture of telomerase even when using methods not based on immunomagnetic separation of cancer cells.
- the telomerase complex can still be isolated and separated from the lysate without centrifugation, which will be more lenient to the functional enzyme.
- Another advantage using a solid phase like magnetic beads for telomerase capture, is presumably the yield of the isolation procedure.
- the solid support may be any of the well known supports or matrices which are currently widely used or proposed for immobilisation, separation, purification etc. These may take the form of particles, sheets, filters, membranes, fibres, capillaries, microtitre strips, tubes, plates, well or biochips etc.
- the support may be made of glass, silica, latex, cellulose, agarose or any polymeric material. Preferred are materials presenting a high surface area for binding of the telomerase complex and other proteins or protein complexes. Such supports will generally have an irregular surface and may be for example be porous or particulate eg. particles, fibres, webs, sinters or sieves. Particulate materials eg. beads are generally preferred due to their greater binding capacity, particularly polymeric beads.
- a particulate solid support used according to the invention will comprise spherical beads.
- the size of the beads is not critical, but they may for example be of the order
- beads of diameter 2.8 ⁇ m and 4.5 ⁇ m have been shown to work well.
- Monodisperse particles that is those which are substantially uniform in size eg. size having a diameter standard deviation of less than 25 %, preferably less than 10 % and more preferably less than 5 %, have the advantage that they provide very uniform reproducibility of reaction.
- Monodisperse polymer particles produced by the technique described in US-A-4336173 are especially suitable.
- Non-magnetic polymer beads suitable for use in the method of the invention are available from Dyno particles AS (Lillestr ⁇ m, Norway), as well as Seradyn (Indianapolis, US), Qiagen (Germany), Amersham Pharmacia (UK) and others. Magnetic particles suitable for use in the method of the invention are aviable from Dynal (Oslo, Norway), Seradyn (Indianapolis, US), Scigen (Sittingbourne, UK) and others.
- magnetic beads are preferred.
- magnetic as used herein means that the support is capable of having a magnetic moment imparted to it when placed in a magnetic field, and thus is displaceable under the action of that field.
- a support comprising magnetic particles may readily be removed by magnetic aggregation, which provides a quick, simple and efficient way of separating the particles following the cell and molecular binding steps, and is a far less rigorous method than traditional techniques such as centrifugation which generate shear forces which may disrupt cells, degrade molecules or destroy the biological activity of the isolated component.
- the magnetic particles with telomerase complex and other proteins or RNA-protein complexes attached may be removed onto a suitable surface by application of a magnetic field eg. using a permanent magnet. It is usually sufficient to apply a magnet to the side of the vessel containing the sample mixture to aggregate the particles to the wall of the vessel and to pour away the remainder of the sample.
- super-paramagnetic particles for example those described by Sintef in EP-A-106873, as magnetic aggregation and clumping of the particles during the reaction can be avoided, thus ensuring uniform isolation the biological material.
- the well-known magnetic particles sold by Dynal AS (Oslo, Norway) as DYNABEADS are particularly suited to use in the present invention.
- Functionalised coated particles for use in the present invention may be prepared by modification of the beads according to US patents 4336173 and 4,459,378 and 4,654,267.
- beads, or other supports may be prepared having different types of functionalised surface, for example positively or negatively charged, hydrophilic or hydrophobic.
- Different molecular components exhibit different degrees of non-specific binding to different surfaces and supports and it may be advantageous to "titrate" the amount of solid support (eg. the number of particles) per volume unit, in order to optimise the binding conditions, and determine the optimum support area eg. particle concentration for a given system.
- the cell sample, isolated or support-bound cells are lysed to release their components including telomerase complexes.
- Methods of cell lysis are well known in the art and widely described in the literature and any of the known methods may be used. Different methods may be more appropriate for different sample types and different cells, but to keep the biological activity of the target components it is important to use an appropriate lysis method with appropriate buffers and mechanical lysis.
- the cells may be isolated by any means like centrifugation of liquid samples, needle biopsies, buccal scrapes, preferentially for the method of the invention cells are enriched by using a solid support and the support-bound cells may conveniently be removed or separated from the remainder of the sample, thereby concentrating or enriching the cells.
- the cell binding step serves to enrich the cells and/or to concentrate them in a smaller volume than the initial sample.
- Lysis may then conveniently be achieved by adding an appropriate lysis buffer containing the desired lysis agents or by subjecting the isolated cells to the desired lysis conditions. For example, in the case of simply adding a lysis buffer containing the appropriate lysis agents, the isolated cells may simply be
- telomere activity 759 of 895 (i.e. 85%) of the malignant tumours tested were shown to express this enzyme (Shay and Bacchetti, 1997), a result that can be utilised to distinguish malignant from non-malignant tumours (Sommerfeld et al., 1996; Hiyama et al., 1996b; Sugino et al., 1996; Kyo et al, 1997; Murakami et al, 1997; Yoshida et al, 1998).
- tumour cells were isolated using Nycoprep (Nycomed Pharma AS), a method based on the same principles as Lymphoprep. But it was observed that the centrifugation steps in the enrichment procedure caused inactivation of telomerase and reduced the number of tumour
- Murakami et al. (1998) described the problem centrifugation entails on telomerase activity, but by using immunomagnetic isolation of cancer cells and telomerase this problem is avoided; there will be no need for a time consuming step for culturing of cells before performing the TRAP assay because interfering agents are removed before enzymatic elongation of the telomere and PCR amplification.
- telomerase activity was detected in the pancreatic juice 19 months before the affected person got the diagnosis of pancreatic cancer using computed tomography for screening (Suehara et al., 1998).
- telomere assay could be in the diagnosis of cancer through obtainable body fluids such as blood, bone marrow, urine, sputum, and materials derived from various washes as demonstrated by isolation and detection of telomerase in pleura (Example 9). Fine needle biopsies, cervical smears and analysis of cells in the faeces might also be useful for improved early diagnosis of primary cancer.
- Example 8 Detection of micrometastasis in blood was demonstrated in Example 8 with immunomagnetic enrichment of cancer cells and telomerase capture in combination with detection of telomerase activity.
- Several independent experiments showed a sensitivity of 2-3 cancer cells per million normal cells, which should demonstrate both the sensitivity and the reliability of this method.
- the same protocol was tested on clinical material, which resulted in detection of micrometastatic cells in pleura from breast cancer patients ( Figure 1 1 ). Telomerase activity was 22
- RECTIFIED SHEET (RULE 91) found mainly in the bead fraction but some activity was also found in the remaining lysate. This result can be explained by presence of more telomerase complexes in the samples tested than the beads were able to capture.
- This invention describes a novel method for detection of micrometastasis; circulating cancer cells were enriched following an immunomagnetic isolation protocol (Bosnes et al., 1997), telomerase was isolated and then detected using the TRAP assay (Kim et al., 1994). Immunomagnetic isolation and TRAP assay are both recognised methods in molecular biology, but the combination of these two methods has never been described earlier. Enrichment of circulating carcinoma and isolation of telomerase in combination with detection of enzymatic activity can be a contribution in the use of telomerase as both a diagnostic and a prognostic marker.
- this invention describes a method for improved telomerase detection and in addition how this method is combined with targeting cells of interest by cell sorting prior to telomerase detection.
- This method is positive selection of circulating carcinoma cells in blood or bone marrow combined with telomerase detection.
- a method for telomerase detection by isolating the telomerase complex from crude cell lysates using a solid-phase and preferentially magnetic beads isolating the telomerase complex from crude cell lysates using a solid-phase and preferentially magnetic beads.
- a method for telomerase detection in target cells by positive enrichment of target cells or depletion of unwanted cells like telomerase-competent stem cells, or a combination of positive and negative enrichment strategies to target only cells of interest and removing cells interfering with the assay.
- telomerase detection by combining telomerase isolation with detection of telomerase subunits like telomerase RNA. This method detects only components integrated in telomerase complexes and will not detect free subunits in the cell.
- telomerase activity in clinical samples with rare cells requires a sensitive assay.
- the aim of this example was to determine the sensitivity of the telomerase repeat assay without any radioactive labelling. To do so, a series of samples with increasing number of cells 40 to 1000 were set up. The telomerase activity - TRAP assay - was measured in each case ( Figure 3), following the original TRAPeze protocol (Oncor).
- SW480 cultured cells of epithelial origin were washed twice in PBS and collected by centrifugation at 600x g for 10 minutes at 4°C.
- the supernatant was discarded and the cells were lysed in 20 ⁇ l CHAPS lysis buffer and incubated for 25-30 minutes on ice.
- telomerase assay a mix was prepared:
- BSA Bovine serum albumin
- dNTP MIX 2.5 mM each of dATP, dTTP, dGTP, dCTP
- Figure 3 shows that the detection limit without radioactive labelling of the oligonucleotide for this telomerase detection method, is somewhere between 40-50 SW480 cells.
- the telomerase positive bands increase in strength with increasing number of cells with the exception of 100 cells sample which in this experiment did not show as much telomerase activity as expected.
- the manufacturer of the TRAPeze kit shows telomerase activity in an extract from 80 telomerase positive cells in their documentation.
- telomerase assay (TRAPeze kit, Oncor, US). This was a simulation of immunomagnetic separation of cells since the cell line S W480 would bind to the anti-Epithelial Dynabeads through the BerEP4 antibodies on the beads. The cells captured onto the magnetic beads were lysed and the beads were separated from the lysate. Both the bead fraction and the remaining lysate were tested for telomerase activity.
- telomerase-mediated extension of the TS-primer 25 Incubation 30 minutes at 30°C for telomerase-mediated extension of the TS-primer. Amplification procedure directly following the extension: 94°C for 90 sec followed by 30 cycles of 94°C for 30 sec, 60° C for 30 sec. Separation of the PCR products by electrophoresis on a 12.5 % acrylamide gel.
- telomerase-positive SW480 cells 1000 were lysed in the presence of magnetic beads (Dynabeads M-280 anti-Epithelial Cell), whereas 1, 10 or 20 million magnetic beads were used.
- the beads were withdrawn from the sample using a magnet at the tube wall (Dynal MPC-E) and the lysate was transferred to a new tube. The beads were suspended in CHAPS lysis buffer. Both the bead fractions and the remaining lysates were tested for telomerase activity as shown in Figure 4. Positive telomerase signals were only seen in the bead fractions and best results were obtained using 20 million magnetic beads.
- telomerase complexes surprisingly are bound directly or indirectly to the magnetic beads after cell lysis in the TRAPeze lysis buffer.
- the magnetic beads were removed prior to the telomerase assay, no activity was detected (result not shown).
- the capture of telomerase onto magnetic beads did not destroy the biological activity of the enzyme complex. This implies that the telomerase activity can be tested by isolating the telomerase using magnetic beads and the lysate with inhibitors can be removed prior to TRAP test.
- Best results for capture of the telomerase complex were obtained with 20 million Dynabeads (300 ⁇ g) when using 1,000 SW480 cultured cells.
- Example 3 Isolation of the telomerase complex using Dynabeads DNA DIRECT
- telomerase was isolated using antibody-coated magnetic beads.
- telomerase was isolated using antibody-coated magnetic beads.
- Variable amounts of Dynabeads DNA DIRECT (Dynal, Oslo, Norway) were used to isolate telomerase activity from 2000 SW480 cells. The same method as in Example 2 was used.
- the telomerase complex can be isolated from a cell lysate with uncoated magnetic beads normally used for DNA isolation.
- uncoated magnetic beads normally used for DNA isolation.
- the optimal amount of DNA DIRECT beads to be used for telomerase isolation is between 20 - 30 million or 300 - 450 ⁇ g.
- Example 4 Isolation of telomerase with uncoated epoxide beads.
- Figure 6 shows how the signal intensity of PCR products in the TRAP assay was almost identical in the range from 200 ⁇ g to 400 ⁇ g of beads.
- the signal intensity in the lane with 100 ⁇ g beads was not as strong as expected, probably due to loss of cells during isolation in this experiment.
- telomerase complexes were bound to the beads when 200 ⁇ g beads or more were used.
- the explanation is that enough telomerase is isolated and thereby sufficient template is produced to saturate the PCR, when using 200 ⁇ g magnetic beads or more.
- Cells with relative high telomerase activity were used, and as a rule of thumb a minimum of approximately 0.1 ⁇ g of expoxide Dynabeads must be used per cell, to ensure that all or sufficient amount of telomerase complexes are isolated for strong TRAP assay PCR signals. 400 ⁇ g magnetic beads was used in later experiments.
- telomere complex The original hypothesis for the mechanism for binding of telomerase complex to the solid phase, was an indirect binding via chromosomal DNA, i.e. that the beads bound genomic DNA in a chromatin form with the telomerase complex as a part of the chromatin structure.
- telomerase complexes The protocol in example 2 for the isolation of telomerase complexes was used.
- the uncoated epoxide Dynabeads was used for this example in the same way as in example 4. Different amounts of SW480 cells were tested. Each bead fraction was resuspended in 40 ⁇ l water and incubated 5 minutes at 65° for an elution of components bound to the magnetic beads. For the remaining lysates, any genomic DNA was isolated using the commercial kit QIAamp Blood Kit from Qiagen, Germany and the recommended protocol.
- Example 6 Mechanism for solid-phase telomerase isolation: non-specific binding of proteins and protein-RNA complexes to the magnetic beads.
- telomerase complex was isolated following the protocol described in Example 2, using SW480 cells as starting material. The proteins were separated and visualised using SDS-PAGE with subsequent silver staining after heat elution from the beads.
- the tube was placed in a MPC for 2 minutes for the bead/cell complexes to migrate to the tube wall. The supernatant was removed and discarded.
- the bead-bound components were eluted from the beads by placing the tube on 65°C for 5 minutes. The tube was placed in the magnet again to collect the beads and the eluate was transferred The tube was removed from the MPC, 1 ml PBS was added and the complex of beads and cells was resuspended. The beads with cells were collected again with the magnet and the washing was repeated twice. The resuspended complex of beads and cells was transferred to a clean tube before placing it in the MPC for the last washing.
- the beads were collected with the magnet and the bead fraction was suspended in 10 ⁇ l lOmM Tris-HCl. to a clean tube.
- the PhastSystem (Pharmacia Biotech. AB, Sweden) is a SDS-PAGE system for molecular weight measurements and analysis of polypeptides.
- 2 ⁇ l of 5x Red buffer was added to 8 ⁇ l of each of the eluates.
- the tubes containing this mix were placed at 100°C for 5 minutes for a denaturation of the proteins.
- the proteins were dissociated into their respective polypeptide subunits as a result of the added SDS and ⁇ -mercaptoethanol.
- the tubes were stored on ice until gel loading of the samples.
- the proteins were separated on a 10-15 % gradient gel by electrophoresis at a constant voltage and constant pH.
- PhastGel Silver Kit (Pharmacia Biotech. AB, Sweden) was used for visualisation of the proteins on the gel. With silver staining proteins can be detected with a concentration down to
- the proteins bind roughly the same amount of sodium dodecyl sulphate (SDS) per weight unit and take on a net negative charge, rendering the intrinsic charge of the protein insignificant.
- SDS sodium dodecyl sulphate
- the native conformation of a protein is altered when SDS is bound, and most proteins assume a similar shape, and thus a similar ratio of charge to mass. Separation will therefore depend on the molecular weight of the polypeptides alone.
- the mobility of the proteins is relatively unaffected by the polyacrylamide gel when the electrophoresis starts. When the proteins reach the gradient gel interface, their mobility is drastically reduced due to the sudden decrease in pore size, and the moving boundary rapidly migrates away from the proteins. The proteins unstack and migrate at a uniform voltage and at constant pH. As the proteins migrate through the gradient gel (10-15%), they separate according to their size.
- Example 2 shows how reliable the method is even when using only a small quantity of cells in the sample.
- the protocol for isolation of telomerase (Example 2) was followed, 50 cells were used in each parallel, as this was close to the detection limit in the method developed (Example 1).
- the solution is to sort the cells prior to telomerase measurement. This can be done by isolating the cells of interest for example by using monoclonal antibodies towards cell surface markers like the BerEP4 against a common epitope of epithelial cells. Alternatively, cells that can interfere with the results can be removed by depletion for example removing T-lymphocytes by using magnetic beads coated with antibodies towards CD2. Very clean cell populations can be obtained by using a combination of positive selection or target cells and depletion of unwanted cells (Neurauter, A. et al. 1998).
- cancer cells in blood will be at a very low number compared with the nucleated leukocytes in blood, down to 1 cancer cell per million normal cells or less.
- a positive selection of cancer cells can be employed by taking advantage of the fact that the cancer cells are at an «unnormal» site.
- Carcinoma is the major group of cancers and originates from epithelial cells. Epithelial cells, even cancerous types, express certain common epithelial cell markers. Antibodies towards such epithelial cell markers (e.g.
- BerEP4 can be used to isolate/enrich epithelial cells by coupling such antibodies to a solid phase like magnetic beads (Hardingham et al. 1993, 1995, Borgnes et al. 1996, Naume et al. 1997). We have obtained a 3 log enrichment of the cancer cells with a recovery of about 70 % (Borgnes et al. 1996, Naume et al. 1997).
- PBL peripheral blood cells
- SW480 cultured cells
- telomerase assay a mixture was prepared as described in example 1. Incubation 30 minutes at 30°C for telomerase-mediated extension of the TS-primer. Amplification procedure directly following the extension: 30 cycles of 94°C for 30 sec, 60° C for 30 sec. Separation of the PCR products by electrophoresis on a 12.5 % acrylamide gel.
- the immobilised cancer cells were lysed in the CHAPS lysis buffer and collecting the beads with a magnet isolated the telomerase complexes.
- Example 9 Detection of micrometastatic cells in pleura.
- lymphocytes which also weakly express telomerase (Blasco et al, 1995; Hiyama, K. et al, 1995; Chiu et al, 1996), in the 12.5 ml pleura sample tested in the experiment shown here. It was likely that the patient had circulating cancer cells in the pleura (personal communication, Dr. Gunnar Kvalheim), but the quantity of cancer cells was unknown. 20 million Dynabeads anti-Epithelial Cell were added for enrichment of cancer cells as in Example 8.
- the remaining cells in the pleura were lysed in lx CHAPS lysis buffer with 400 ⁇ g epoxide beads to reveal presence of the telomerase expressing lymphocytes cancer cells not captured by Dynabeads anti-Epithelial Cell.
- the protocol described in Example 2 and 8 was followed.
- Figure 11 shows that telomerase was detected in the enriched cell population of pleura. There seems to be some activity in the lysate fraction of this enriched population as well, which may be an indication that the number of beads added was too small for this strong telomerase activity.
- This experiment should show that the method for isolation of carcinoma cells with subsequent detection of telomerase activity is functional when testing on a real sample as well as when tested in the model system.
- Example 10 Combination of telomerase assay and CK19 assay for micrometastasis detection
- the technology presently used for detection of circulating micrometastasis is based on microscopic detection of cancer cells. This can be made easier by selective staining of cancer cells made possible by cells present at an unnormal location. An example of this is staining of cytokeratin in carcinoma cells found in blood or bone marrow. Another possibility is isolation of mRNA with subsequent amplification of genes expressed more or less specifically in cancer cells.
- Cytokeratin 19 (CK-19) is one of the markers used for detection of micrometastasis using the mRNA approach.
- TRAP assay can be used for detection of the enzymatic activity of telomerase (Example 1), which is one of the most specific cancer markers known.
- telomerase a sequence of cancer markers known.
- a RT-PCR amplification of it can give a positive result if the blood sample is contaminated with normal epithelial cells, even though there are no circulating carcinoma present.
- Table B shows a comparison of the methods most frequently used for detection of micrometastasis. All methods are sensitive, but detection based on measurement of telomerase activity is the only method that requires living cells.
- telomerase activity is a biological phenomenon restricted to certain stem cells (Wright et al, 1996; Harle-Bachor et al, 1996; Ramierez et al, 1997; Kyo et al, 1997; Burger et al, 1997), haemopoitetic cells (Broccoli et al, 1995; Hiyama, K. et al, 1995) and tumour cells (Kim et al, 1994; Shay and Bacchetti, 1997).
- This specific expression pattern can be utilised to detect circulating carcinoma without considering contamination of normal telomerase negative epithelial cells. When using immunomagnetic enrichment of cells, contamination of telomerase expressing leukocytes will also be avoided.
- the TRAP assay measures an enzyme activity implies that it is dependent on the presence of intact cells expressing this enzyme. Thus, the TRAP assay may be a good indicator of viable as opposed to dead tumour cells. This is important because the medical
- telomere is exceptionally stable at room temperature, eliminating the need for special or rapid handling procedures at the time of specimen collection (Duggan et al, 1998). This result was confirmed, as it was no problem with detection of telomerase activity in the one-day old pleura sample tested. No difference in activity was shown when the one- day old pleura sample was compared with fresh samples tested the same day as collected from the patient (data not shown).
- Figure 12 shov/s the combination of the telomerase isolation with the TRAP assay and mRNA isolatation from the lysate, with CK-19 as a marker.
- the bead traction can be used as usual for detection of telomerase activity with removal of interfering agents prior to the TRAP assay.
- Oligo-dT beads can be added to the lysate for isolation of polyadenylated mRNA using primers specific for CK-19 for detection of circulating cancer cells. In this way two independent tests, both very sensitive, can be performed on the same sample to diagnose micrometastasis with a high degree of reliability.
- RNA component has been cloned for the human template gene (Feng et al. 1995). Expression of the telomerase RNA is not correlated with telomerase activity, although expression is shown to be upregulated in cells that are highly positive for telomerase (Avilon et al. 1996, Blasco et al. 1996). The presence of telomerase RNA in cells with no telomerase activity may indicate a surplus of RNA component or inactivated telomerase complexes. The use of the RNA component for diagnosis is therefore not straightforward and presently not thought to be predictive of cancer. Telomerase RNA is not polyadenylated in humans and traditional method of total RNA isolation has been used for detection of this component.
- RNA component can be used as a diagnostic tool.
- the telomerase complex can be isolated by the magnetic beads and thereby the RNA component that is integrated in the intact complexes. However, free RNA component will not be isolated with this method.
- the RNA component may be isolated from the complex by
- Example 12 Isolation of colonic cells from faeces combined with telomerase assay
- Telomerase activity was detected in luminal washings from colectomy specimens from 60% of tested carcinoma cases but not in cases of inflammatory bowel diseases, suggesting that it can be a good marker for the detection of colon carcinoma (Yoshida et al. 1997a).
- a method for isolating cells from stool has been ( eveloped and patented (O'Neill 1995). The method comprises steps of a) cooling the stool to a temperature below its gel freezing point and b) removing cells using immunomagnetic beads whilst the stool remains substantially intact. Alternatively exfoliated cells can be captured from colon washings also by a immunomagnetic method.
- the immunomagnetically isolated cells are lysed in the presence of excess magnetic beads to capture the telomerase complexes.
- the telomerase complexes are concentrated and the rest of the lysate is discarded. In this way the telomerase activity can be measured by TRAP assay or by amplifying the RNA component.
- One advantage of this method is, fhat any inhibiting substances from the stool sample can be removed prior to telomerase measurement.
- the stool sample is excreted directly into a collection bag which is closed and placed in ice- water.
- the cooling is performed for at least 30 min.
- the buffer should contain 50mM N-acetylcysteine, 3mM sodium butyrate, antibiotics, sodium bicarbonate (lg/Iitre) and BSA (lOg/I).
- the N-acetylcysteine should be prepared fresh. Smaller samples of the stool could be used and proportionally less buffer.
- the washing solution containing the suspension of cells is removed from the bag, 0.4 gram of boric acid is added per ml of washing solution to adjust the pH.
- Dynabeads BerEP4 (4.5 ⁇ M) are added per ml of cell suspension.
- the beads may be added suspended in PBS.
- the sample is incubated on a rotator at 4°C to allow for antibody-antigen immobilisation of the cells to the magnetic beads.
- the immobilised cells are collected at the tube wall with a magnet (Dynal MPC) and the supernatant is removed and discarded.
- the cell-bead complexes are washed in PBS by gentle stirring for 2 minutes, collected with a magnet and the washing solution is discarded.
- the washing step must be repeated several times until no brown colour is seen in the washing solution.
- the immobilised cells are lysed in a CHAPS lysis buffer (example 1) in the presence of sufficient amount of beads. Usually the amount is doubled by addition of DNA DIRECT magnetic beads.
- the beads with any telomerase complexes are collected at the tube wall with a magnet.
- the isolated material is ready for telomerase assaying.
- Example 13 Isolation of epithelial cells from urine and sputum/buccal swabs combined with telomerase isolation and telomerase assay.
- telomerase activity was detected in 62% of bladder carcinoma patients, whereas weak signals were seen in 3 of 83 non-malignant urine samples (Yoshida et al. 1997b.
- Exfoliated cells were collected from 50 ml urine by centrifugation.
- the method described here uses immunomagnetic beads coated with antibodies towards epithelial cells to collect exfoliated cells from urine, sputum or other body fluids. The advantage of this is the removal of interfering substances like bacteria and debris.
- the telomerase complexes are isolated with magnetic beads from the cell lysate and analysed after removal of the rest of the lysate.
- Urine preferably the first urine of the day, is collected and cooled on ice.
- the magnetic beads with captured cells are collected with a strong magnet (Dynal MPC) and the urine carefully discarded.
- the cell-bead complexes are washed twice in cold PBS before telomerase isolation.
- Saliva or sputum is collected in a bottle and diluted with ice-cold isotonic solution containing a mucolytic agent such as the suspending solution in example 5. Eating should be avoided for several hours prior to sample collection. For examination of the respiratory system the mouth should be cleaned with water prior to muco-ciliary clearance or coughing.
- immunomagnetic beads preferably 4.5 ⁇ M coated with BerEP4 are added (30 million). The sample is rotated for 5-20 minutes to allow for cell immobilisation.
- the magnetic beads with captured cells are collected with a strong magnet (Dynal MPC) and the saliva/sputum carefully discarded.
- the cell-bead complexes are washed twice in cold PBS before telomerase isolation.
- the immobilised cells are lysed in a CHAPS lysis buffer (example 1) in the presence of sufficient amount of beads. Usually the amount is doubled by addition of DNA DIRECT magnetic beads.
- the beads with any telomerase complexes are collected at the tube wall with a magnet.
- the isolated material is ready for telomerase assaying.
- telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells Correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs.
- telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum. Mol. Gen. 6: 921-926.
- telomerase activity Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow.
- telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11: 1921-1929.
- Cellular immortality a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol. Carcinog. 13: 254- 265.
- RNA component of human telomerase Science 269: 1236-1241.
- telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51 : 887-898.
- Immunobead-PCR a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 53: 3455-3458.
- hTERT is a critical determinant of telomerase activity in renal-cell carcinoma. Int. J. Cancer 78: 539-543.
- telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59: 521-529.
- TLP1 A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88: 875-884.
- telomere activity in malignant and non-malignant skin conditions. J. Invest. Dermatol. 106: 759-765.
- telomeric repeat amplification protocol (TRAP)
- Lane 1 control with no cells
- lane 2 40 cells
- lane 3 50 cells
- lane 4 75 cells
- lane 5 100 cells
- lane 6 500 cells
- lane 7 positive control
- lane 8 negative PCR control.
- Lane L molecular weight ladder (10 bp)
- Lane 1 lysate fraction - using 1 million Dynabeads (15 ⁇ g)
- Lane 2 bead fraction - using 1 million Dynabeads
- Lane 3 lysate fraction - using 10 million Dynabeads (150 ⁇ g)
- Lane 4 bead fraction - using 10 million Dynabeads
- Lane 5 lysate fraction - using 20 million Dynabeads (300 ⁇ g)
- Lane 7 Lysate of 1000 SW480 cells - tested without fractionation
- Lane 1 lysate fraction - using 10 million Dynabeads (150 ⁇ g)
- Lane 2 bead fraction - using 10 million Dynabeads
- Lane 3 lysate fraction - using 20 million Dynabeads (300 ⁇ g)
- Lane 4 bead fraction - using 20 million Dynabeads
- Lane 5 lysate fraction - using 30 million Dynabeads (450 ⁇ g)
- Lane 6 bead fraction - using 30 million Dynabeads
- Lane 1 50 ⁇ g beads
- lane2 100 ⁇ g beads
- lane 3 150 ⁇ g beads
- lane 4 200 ⁇ g beads
- lane 5 250 ⁇ g beads
- lane 6 300 ⁇ g beads
- lane 7 350 ⁇ g beads
- lane 8 400 ⁇ g beads
- lane 9 positive TRAP assay control
- lane 10 negative PCR control.
- Lane 1+2 10,000 cells and the eluate of the bead bound material
- lane 3+4 5000 cells - the eluate of the bead-bound material
- lane 5+6 1,000 cells - eluate of the bead-bound material
- lane 7+8 DNA isolated from the lysate of 10,000 cells
- Lane 9+10 DNA isolated from the lysate of 5,000 cells
- lane 11+12 DNA isolated from lysate of 1,000 cells
- lane 13 positive control - lOng placenta DNA
- lane 14 negative PCR control
- L Molecular weight standard - 100 bp ladder.
- Lane H High molecular weight standard
- Lane L Low molecular weight standard
- Lane 1&2 Eluate from beads (extract from 80 000 cells)
- Lane 3&4 Eluate from beads (extract from 53 000 cells).
- Lanes 1-5 50 cells, Lane 6: positive control, Lane 7: negative control.
- Lane 10 Lane 1: 0 cells; Lane 2: 40 cells; Lane 3: 50 cells; Lane 4: 75 cells; Lane 5: 100 cells; Lane 6: 500 cells; Lane 7: positive control (500 cells directly tested); Lane 8: negative control.
- Lane 11 Lane 1 : Pleura sample (bead-isolated telomerase); Lane 2: Pleura sample (remaining lysate); Lane 3: Remainder of pleura sample (eluate); Lane 4: Remainder of pleura sample (lysate); Lane 5: Positive control (TSR8 template); Lane 6: Negative control.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00901829A EP1149290A1 (en) | 1999-02-02 | 2000-02-01 | Detecting telomerase activity |
AU23127/00A AU2312700A (en) | 1999-02-02 | 2000-02-01 | Detecting telomerase activity |
JP2000597632A JP2002536000A (en) | 1999-02-02 | 2000-02-01 | Detection of telomerase activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9902302.0 | 1999-02-02 | ||
GBGB9902302.0A GB9902302D0 (en) | 1999-02-02 | 1999-02-02 | Detecting enzyume activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000046601A1 true WO2000046601A1 (en) | 2000-08-10 |
Family
ID=10846973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2000/000100 WO2000046601A1 (en) | 1999-02-02 | 2000-02-01 | Detecting telomerase activity |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1149290A1 (en) |
JP (1) | JP2002536000A (en) |
AU (1) | AU2312700A (en) |
GB (1) | GB9902302D0 (en) |
WO (1) | WO2000046601A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002018652A2 (en) * | 2000-08-31 | 2002-03-07 | Oncomedx, Inc. | Method for detection of htr and htert telomerase-associated rna in plasma or serum |
WO2003097874A1 (en) * | 2002-05-15 | 2003-11-27 | Europroteome Ag | Method for parallel preparation of rna and proteins from a tissue sample |
US20110212454A1 (en) * | 2010-02-26 | 2011-09-01 | Geron Corporation | Assay for Telomerase Activity |
CN116042792A (en) * | 2022-09-05 | 2023-05-02 | 杭州拜赛思生物科技有限责任公司 | Telomerase activity gene detection kit, primer set, probe primer and detection method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997015687A1 (en) * | 1995-06-07 | 1997-05-01 | Geron Corporation | Telomerase activity assays |
US5648215A (en) * | 1992-05-13 | 1997-07-15 | Board Of Regents, The University Of Texas System | Telomerase diagnostic methods |
WO1998037241A1 (en) * | 1997-02-24 | 1998-08-27 | Tm Technologies, Inc. | Telomerase extension assay |
-
1999
- 1999-02-02 GB GBGB9902302.0A patent/GB9902302D0/en not_active Ceased
-
2000
- 2000-02-01 AU AU23127/00A patent/AU2312700A/en not_active Abandoned
- 2000-02-01 WO PCT/IB2000/000100 patent/WO2000046601A1/en not_active Application Discontinuation
- 2000-02-01 EP EP00901829A patent/EP1149290A1/en not_active Withdrawn
- 2000-02-01 JP JP2000597632A patent/JP2002536000A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648215A (en) * | 1992-05-13 | 1997-07-15 | Board Of Regents, The University Of Texas System | Telomerase diagnostic methods |
WO1997015687A1 (en) * | 1995-06-07 | 1997-05-01 | Geron Corporation | Telomerase activity assays |
WO1998037241A1 (en) * | 1997-02-24 | 1998-08-27 | Tm Technologies, Inc. | Telomerase extension assay |
Non-Patent Citations (2)
Title |
---|
BROCCOLI D. ET AL.: "Telomerase activity in normal and malignant hematopoietic cells", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 9082 - 9086, XP002138760 * |
KIM N.W. ET AL.: "Specific association of human telomerase activity with immortal cells and cancer", SCIENCE, vol. 266, 1994, pages 2011 - 2015, XP002138759 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6607898B1 (en) | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
US7910336B2 (en) | 1996-03-26 | 2011-03-22 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
WO2002018652A2 (en) * | 2000-08-31 | 2002-03-07 | Oncomedx, Inc. | Method for detection of htr and htert telomerase-associated rna in plasma or serum |
WO2002018652A3 (en) * | 2000-08-31 | 2003-05-22 | Oncomedx Inc | Method for detection of htr and htert telomerase-associated rna in plasma or serum |
WO2003097874A1 (en) * | 2002-05-15 | 2003-11-27 | Europroteome Ag | Method for parallel preparation of rna and proteins from a tissue sample |
US20110212454A1 (en) * | 2010-02-26 | 2011-09-01 | Geron Corporation | Assay for Telomerase Activity |
US9249452B2 (en) * | 2010-02-26 | 2016-02-02 | Zhu Zhen Pirot | Method of detecting and assaying telomerase activity of telomerase bound by anti-telomerase antibodies |
CN116042792A (en) * | 2022-09-05 | 2023-05-02 | 杭州拜赛思生物科技有限责任公司 | Telomerase activity gene detection kit, primer set, probe primer and detection method |
Also Published As
Publication number | Publication date |
---|---|
JP2002536000A (en) | 2002-10-29 |
AU2312700A (en) | 2000-08-25 |
EP1149290A1 (en) | 2001-10-31 |
GB9902302D0 (en) | 1999-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Saldanha et al. | Analysis of telomerase activity and detection of its catalytic subunit, hTERT | |
Kim | Clinical implications of telomerase in cancer | |
JP4145953B2 (en) | MDA-7 gene | |
US5863726A (en) | Telomerase activity assays | |
Dhaene et al. | Telomeres, telomerase and cancer: an up-date | |
Deutsch et al. | Down-regulation of BRCA1 in BCR-ABL–expressing hematopoietic cells | |
US5804380A (en) | Telomerase activity assays | |
Alegre et al. | Circulating biomarkers in malignant melanoma | |
US20040018551A1 (en) | Quantitative measurement of gene expression based on isolation of RNA from formalin-fixed paraffin-embedded tissue specimens | |
Nawaz et al. | Telomerase expression in human breast cancer with and without lymph node metastases | |
US6821726B1 (en) | Method for quantitatively analyzing tumor cells in a body fluid and test kits suited therefor | |
JP2006510369A (en) | Separation method of cell fraction | |
Novakovic et al. | Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer | |
Kunimura et al. | Telomerase activity in a specific cell subset co-expressing integrinβ1/EGFR but not p75NGFR/bcl2/integrin β4 in normal human epithelial cells | |
Urquidi et al. | Telomerase in cancer: clinical applications | |
Kyo et al. | Telomerase activity in cancer as a diagnostic and therapeutic target | |
EP1149290A1 (en) | Detecting telomerase activity | |
JP6918062B2 (en) | How to evaluate the differentiation status of cells | |
Kinoshita et al. | Low frequency of positive telomerase activity in a chromophobe subtype of renal cell carcinoma | |
Lee et al. | Concurrence of replicative senescence and elevated expression of p16INK4A with subculture-induced but not calcium-induced differentiation in normal human oral keratinocytes | |
KR101807356B1 (en) | Predicting kit for survival of brain cancer patients and the method of providing the information for predicting survival of brain cancer patients | |
Heine et al. | Hodgkin and Reed–Sternberg cells of classical Hodgkin's disease overexpress the telomerase RNA template (hTR) | |
Müller et al. | Telomerase activity in malignant and benign renal tumors | |
Fujiwara-Akita et al. | Expression of human telomerase reverse transcriptase splice variants is well correlated with low telomerase activity in osteosarcoma cell lines | |
Fujiwara et al. | Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 597632 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000901829 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000901829 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09890567 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000901829 Country of ref document: EP |